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For the past several decades, there has been little improvement in the morbidity andmortality associated with Acanthamoeba
keratitis and Acanthamoeba encephalitis, respectively. The discovery of a plethora of antiacanthamoebic compounds has not
yielded effective marketed chemotherapeutics. The rate of development of novel antiacanthamoebic chemotherapies of transla-
tional value and the lack of interest of the pharmaceutical industry in developing such chemotherapies have been disappointing.
On the other hand, the market for contact lenses/contact lens disinfectants is a multi-billion-dollar industry and has been suc-
cessful and profitable. A better understanding of drugs, their targets, andmechanisms of action will facilitate the development of
more-effective chemotherapies. Here, we review the progress toward phenotypic drug discovery, emphasizing the shortcomings
of useable therapies.
Antimicrobial chemotherapy is the most widely used methodof treating infections due toAcanthamoeba. Despite advances
in antimicrobial chemotherapy, the morbidity and mortality as-
sociated with Acanthamoeba keratitis and Acanthamoeba enceph-
alitis, respectively, have remainedhigh. For example, themortality
rate of granulomatous amoebic encephalitis due to pathogenic
Acanthamoeba spp. is more than 90%, even with treatment with
various combinations of drugs such as amphotericin B, rifampin,
trimethoprim-sulfamethoxazole, ketoconazole, fluconazole, sul-
fadiazine, miltefosine, albendazole, etc. (reviewed in references 1,
2, 3, 4, 5, 6, 7, and 8). Current treatment ofAcanthamoeba keratitis
involves chlorhexidine, in combination with diamidines and neo-
mycin, and can last up to a year, and even then infection recur-
rence occurs in approximately 10% of cases (reviewed in refer-
ences 1, 2, 3, 4, 5, 6, 7, and 8). In part, this is due to our incomplete
understanding of the biology of the parasite and of the pathogen-
esis and pathophysiology of the disease, as well as to the lack of
effective chemotherapeutic agents and/or the lack of clinical test-
ing of the potential targets that have been shown to play an im-
portant role in the virulence of pathogenic Acanthamoeba. This is
despite the fact that a plethora of drugs, some of which show
potent antiacanthamoebic effects, have been tested; however,
their translational value in the treatment of Acanthamoeba infec-
tions remains unclear (reviewed in reference 9).Many of the drugs
tested target functional aspects of Acanthamoeba, as it is “easier to
erase function of an organism than its structure” (9). However,
there are disadvantages to this approach. Being eukaryotes, Acan-
thamoeba species share functional homologies with mammalian
cells. Consequently, many of the available drugs cannot be pre-
scribed at effective concentrations due to their unwanted side ef-
fects. This is particularly relevant for treatment of amoebal brain
infection, in which drugs are given intravenously and are expected
to cross the blood-brain barrier to access the central nervous sys-
tem to target the intracerebral parasite. In this process, drugs pen-
etratemany tissues and can affect their physiology before reaching
the target site at an effective concentration. Hence, there is a need
to develop a targeted therapeutic approach, i.e., to identify drugs
that can affect Acanthamoeba viability without affecting the host
cells. The purpose of this review is to classify the tested antiacan-
thamoebic agents into functional groups to identify drugs and/or
chemotherapeutic approaches of potential value for further work.
The knowledge of the mode of action of the majority of drugs
tested against Acanthamoeba is largely derived from studies con-
ducted in bacterial, fungal, or protozoan pathogens. These are
indicated here for information; however, future studies are
needed to determine and/or confirm their mechanism of action
against Acanthamoeba.
MEMBRANE-ACTING AGENTS
Being the outermost surface of the cell, the outer plasma mem-
brane and its constituents provide a logical target(s) as it is easier
to access. With the actively growing infective trophozoite that un-
dergoes binary fission, the properties and charge of the cell mem-
brane and its biosynthesis and modulation offer chemotherapeu-
tic opportunities. Repurposing drugswith knownmodes of action
for the aforementioned targets and/or agents with growth-inhib-
itory effects has been a useful avenue, but this approach lacks
specificity, produces host cell toxicity, andmay not be appropriate
for the dormant cyst stage and thus poses a challenge in wider
application of such drugs against Acanthamoeba infections. For
example, chlorhexidine is positively charged and ionic with the
negatively charged plasma membrane of the parasite, resulting in
structural and permeability changes, ionic leakage, and cytoplas-
mic disruptions causing cellular damage and cell death, although
those effects have not curtailed the use of the compound. It exhib-
its potent amoebicidal properties as well as cysticidal properties at
200g per ml (0.02%), and it is used clinically against Acantham-
oeba keratitis but is not a drug of choice for ocular and brain
infection (10–21) (Table 1). Similarly, biguanide compounds
(polyhexamethylene biguanide [polyhexadine or polyaminopro-
pyl biguanide]) are known to interact with membrane phospho-
lipids, affectingmembrane fluidity and conformation and leading
to ionic leakage and cell death at 200 g per ml (0.02%), and are
used clinically againstAcanthamoeba keratitis butmay exhibit side
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effects and are not ideal for the treatment of ocular or brain infec-
tions, albeit they can be used in combination with chlorhexidine
(10–13, 22–36). More recently, alexidine, an amphipathic bis-
biguanide, has shown amoebicidal activity at 10 g per ml and
cysticidal activity at 100g per ml (37). The cytotoxic activities of
alexidine are comparable to those of chlorhexidine; however,
alexidine appeared less toxic in vivo (37). Several antibacterials
have been tested inAcanthamoeba infection, including polymyxin
B (binds to negatively charged membranes and disrupts mem-
brane integrity) (18, 38–40), cefazolin (18), and meropenem (in-
hibits penicillin binding proteins) (41), but limited antiamoebic
effects were observed at physiologically tolerable concentrations.
Despite similarities to the host’s cell plasmamembrane, ergos-
terol, mannose-binding protein (MBP), and laminin-binding
protein have been identified as useful components for the targeted
killing of amoebae. As the presence of ergosterol is limited to fungi
and protists, while human cells contain cholesterol, this is consid-
ered a useful target, but anti-ergosterol biosynthesis strategies
have shown limited value against Acanthamoeba infections. For
example, several azole compounds, including miconazole nitrate,
ketoconazole, clotrimazole, fluconazole, and voriconazole, have
been tested that target 14- demethylase, a cytochrome P-450
enzyme necessary to convert lanosterol to ergosterol, inhibiting
phospholipid and triglyceride synthesis and affecting oxidative
and peroxidative enzyme activities, resulting in deterioration of
subcellular components and leading to cell necrosis. Although
several azole compounds showed amoebicidal effects at a concen-
tration as low as 10 g per ml in vitro, they showed cysticidal
properties at a far higher concentration of 1,000g perml (19, 20,
27, 31, 33, 40, 42–61). Among the ergosterol inhibitors, ampho-
tericin B has been tested and has been shown to bind to ergosterol,
forming a transmembrane channel that leads to monovalent ion
leakage, which is the primary effect leading to cell death. The ef-
fective concentration against Acanthamoeba is reported to be 100
g per ml (39, 40, 55, 59–63). Additionally, natamycin, which
targets ergosterol in the plasmamembrane, preventing ergosterol-
dependent fusion of vacuoles as well as membrane fusion and
fission, has shown limited amoebicidal properties at physiologi-
cally relevant concentrations (14, 27, 43, 64). In part, this is due to
the fact that the present compounds targeting ergosterol or its
synthetic pathway lack specificity and produce inconsistent results
against various strains/species of Acanthamoeba andmay also tar-
get the host cell P450 enzymes, resulting in side effects (60–65).
Additionally, the effects of these compounds are often amoebi-
static, rather than amoebicidal (65); hence, prolonged clinical ap-
plication is needed, which could result in the emergence of drug-
resistant strains, as seen in yeast, where azole resistance emerging
through increased function of efflux mechanisms or through
changes in the azole targets, e.g., C14 demethylase, or through
changes in the biosynthetic steps of ergosterol synthesis has been
observed. Similar mechanisms may explain variations in antimi-
crobial sensitivity among various isolates of Acanthamoeba (66).
Overall, the ergosterol biosynthesis pathway is a potential target in
the rational development of targeted therapeutic interventions
against Acanthamoeba, as long as specificity is achieved to opti-
mize the antiparasitic effects.
Within the plasma membrane, mannose-binding protein
(MBP) has been identified as a key adhesin in Acanthamoeba-
mediated host cell binding and cytotoxicity. The MBP protein
consists of a signal peptide (amino acids 1 to 21), an extracellular
cysteine (C)-rich region covering amino acid positions 274 to 615,
and a single predicted transmembrane region (amino acids 733 to
755). Expression of MBP is linked with the pathogenicity of
Acanthamoeba and is associated with binding to and cytotoxicity
of host cells. Notably, immunization with recombinant MBP
(rMBP) protects animals against subsequent challenge with
pathogenic Acanthamoeba species (5). Although rMBP is not ap-
plicable as a vaccine tool given the rarity of the disease, these find-
ings have highlighted MBP as an important chemotherapeutic
target. For example, recent studies showed that MBP-targeted
chemotherapy can effectively eradicate amoebae in vitro and pro-
tect host cells against amoeba-mediated damage (66). Although
studies are needed to prove the value of this approach in vivo, it has
been suggested that mannose-conjugated porphyrin may have an
application for targeted photodynamic chemotherapy against
Acanthamoeba infections and should be explored for potential
clinical applications in future investigations (66). Other drugs tar-
geting the membrane include caspofungin, which is known to
inhibit the synthesis of beta-(1,3)-D-glucan (59, 67). Caspofungin
shows amoebicidal properties in vitro at 250 g per ml and is
cysticidal at 500 g per ml (59, 67) and is thus of limited value in
clinical applications.
INTRACELLULAR TARGETING AGENTS
Calcium channels play a critical role in the viability of Acantham-
oeba. For example, the viability of trophozoites depends on their
amoeboid movement in search and uptake of food particles, en-
cystation or excystation, and asexual reproduction. These pro-
cesses involve myosin contractility, activation of actin filament,
inhibition of actin cross-linking by alpha-actinin, or binding to
calmodulin. Other low-molecular-weight calcium-binding pro-
teins and calpain, actophorin, actobindin, calcium-sensitive actin
gelation protein, actin bundling protein (AhABP), and calcium-
dependent extracellular proteases play important roles in its phys-
iology. Thus, drugs affecting these functions would have deleteri-
ous effects on the viability of Acanthamoeba. Notably, calcium
antagonists such as amlodipine (inhibits the transmembrane in-
flux of calcium ions), loperamide (inhibits calcium channel activ-
ity and calmodulin binding), amiodarone (calcium blocker-like
activity), and trifluoperazine dihydrochloride and chlorproma-
zine dihydrochloride (inhibit calmodulin) exhibit amoebicidal ef-
fects in vitro (68). Although the majority of drugs are used clini-
cally, they exhibit antiamoebic effects at a relatively high
concentration of 500g perml. However, two neuroleptic agents,
chlorpromazine and trifluoperazine, show amoebicidal and cysti-
cidal effects in the micromolar range of concentrations in vitro
(69). Furthermore, the combination of chlorpromazinewith roki-
tamycin or amphotericin B enhances protection of host cells
against the parasite (69), suggesting the need for future studies to
test the clinical relevance of these drugs against Acanthamoeba
infections in experimental models as well as in patients.
Quaternary ammonium compounds, including cetyltrimeth-
ylammonium bromide and cetylpyridinium bromide, have been
tested for antiacanthamoebic properties (54). Their effects are
known to result in inactivation of energy-producing enzymes, de-
naturation of essential cell proteins, and disruption of the cell
membrane. Insertion of the ethyl phosphate group into the mol-
ecule of cetyltrimethylammoniumbromide leads to the formation
of alkylphosphocholines (hexadecylphosphocholine/miltefosine). In
vitro studies showed that quaternary ammonium compounds ex-
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hibit higher antiacanthamoebic properties (at concentrations of
20 M) than hexadecylphosphocholine/miltefosine (60 M)
(54) and are promising agents. Another quaternary ammonium
compound, benzethonium chloride (mode of action, induction of
apoptosis) shows amoebicidal effects at500 g per ml (54) and
is of limited utility. More recently, prochlorperazine (a known
antagonist of dopamine [D2] receptor, muscarinic receptor,
and histamine antagonist) and corticosteroids were shown to
exhibit amoebicidal effects at 250 g per ml in vitro, but deter-
minations of their usefulness require further studies (47, 64,
68, 70).
NUCLEIC ACID-ACTING DRUGS
Nucleic acid inhibitors inhibit DNA/RNA synthesis, preventDNA
from functioning as a template, affect the function of polymerases
involved in the replication and transcription of DNA, or interca-
late into the DNA. The antibacterial properties of nucleic inhibi-
tors are well known, making this pathway a useful target, but the
lack of specificity against eukaryotic Acanthamoeba, together with
the high concentrations required to target cysts and the observa-
tion that the majority of nucleic acid inhibitors are toxic or carci-
nogenic, suggests that, with the exception of few compounds, nu-
cleic acid inhibitors are clinically inappropriate or not ideal
candidates as antiacanthamoebic compounds. For example, pro-
flavine hemisulfate exhibits mutagenic effects onDNA by interca-
lating between nucleic acid base pairs and causes base pair dele-
tions and insertions. It has been reported to exhibit amoebicidal
effects at 100 g per ml and cysticidal effects at 1,000 g per ml
(40). The mode of action of hydroxystilbamidine isethionate in-
volves binding extensively and selectively to kinetoplastic DNA,
inhibiting cell division and reproduction. It has also been shown
to bind to RNA and is a significant inhibitor of ribonucleases, and
it is taken up in lysosomes, leading to a significant increase in the
number of lysosome-like bodies and secretion granules. It exhibits
amoebicidal properties at 100 g per ml and cysticidal properties
at 1,000 g per ml (40). Other compounds tested include trim-
ethoprim, which binds to dihydrofolate reductase and inhibits the
reduction of dihydrofolic acid to tetrahydrofolic acid, which is
important in the thymidine synthesis pathway for DNA synthesis.
It has been shown to exhibit amoebicidal effects at 100 g per ml
(39), while 5-fluorocytosine (mode of action, competitive inhibi-
tion of purine and pyrimidine uptake) and moxifloxacin (inhibi-
tor ofDNAgyrase, a type II topoisomerase, and topoisomerase IV,
required for DNA replication), have shown limited value in the
treatment of granulomatous amoebic encephalitis (41, 63). Given
the nonselective nature of these compounds and their associated
toxicity, several studies have tested combinations of nucleic acid
synthesis inhibitors againstAcanthamoeba.When pyrimethamine
(a dihydrofolate reductase inhibitor blocking biosynthesis of pu-
rines and pyrimidines) and sulformethoxine (targeting dihydrop-
teroate synthase and dihydrofolate reductase and competing with
para-aminobenzoic acid for incorporation into folic acid) were
tested in combination, amoebicidal properties were observed at
100 g per ml (39). Similarly, trimethoprim plus pyrimethamine
and trimethoprim plus sulfamethoxazole (inhibitor of folic acid
synthesis) showed amoebicidal effects at 100g perml (39, 50, 51,
71, 72).
Among the effective compounds tested, pentamidine isethio-
nate inhibited synthesis of DNA, RNA, phospholipids, and pro-
teins, with amoebicidal and cysticidal properties seen at100 to
200g permlwith variable results (11, 19, 73), while propamidine
isethionate (DNA synthesis inhibitor) is used clinically against
keratitis at a concentration of up to 1mg perml (13, 16, 17, 23, 27,
32, 33, 35, 36, 38, 42, 46, 53, 70, 74–79). Other drugs tested in-
cluded diminazene aceturate, which binds to the groove between
the complementary strands of DNA at regular intervals and thus
distorts the helical structure. It is also known to affect phospho-
lipids synthesis and also interferes with the glycolytic pathway of
the parasite. It has been shown to exhibit amoebicidal and cysti-
cidal properties at 100 to 200 g per ml (11). For treatment of
brain infections, rifampin is promising as an additive drug, as it is
lipophilic, a property thatmakes it a good candidate for treatment
of infections of the central nervous system, which requires distri-
bution to the central nervous system by penetration through the
blood-brain barrier. The mode of action is inhibition of DNA-
dependent RNA polymerase by binding to its beta-subunit, thus
preventing transcription of RNA and subsequent translation to
proteins. It has been shown to exhibit amoebicidal properties but
is of limited value in treatments (50, 51, 64, 71).
PROTEIN SYNTHESIS-INHIBITING DRUGS
Inhibition of protein synthesis has been one of the key targets for
many of the available antibiotics, mostly taking advantage of dif-
ferences in prokaryotic and eukaryotic ribosome structures and
functions. The majority of protein synthesis inhibitors block
mRNA translation into proteins, e.g., initiation, elongation (in-
cluding aminoacyl tRNA entry, proofreading, peptidyl transfer,
and ribosomal translocation), and termination. As for other path-
ways and structures of eukaryotes, in homology with host mam-
malian cells, selective targeting of protein synthesis remains a
challenge and the use of protein synthesis inhibitors is often asso-
ciated with host cell toxicity. Given that amoebae are actively
growing in their infective states, such compounds can be used to
block reproduction with tolerable toxicities. For example, paro-
momycin sulfate (inhibitor of the initiation and elongation steps
of protein synthesis) has been shown to exhibit amoebistatic,
amoebicidal, and cysticidal properties at more than 100g perml
(33, 40, 54). Tobramycin (inhibitor of protein synthesis by bind-
ing to ribosomes and preventing mRNA translation, leading to
cell death) has shown amoebicidal properties at more than 250g
per ml (25, 80).
Similarly, neomycin sulfate, which binds to four nucleotides of
16S rRNA and a single amino acid of protein S12 and interferes
with the initiation complex, leading to misreading of mRNA such
that incorrect amino acids are inserted into the polypeptide, re-
sulting in nonfunctional or toxic peptides and the breakup of
polysomes into nonfunctional monosomes, has been shown to
exhibit antiamoebic effects at 250 g per ml, but cysticidal prop-
erties are observed at500 g per ml (30, 32, 35, 38, 40, 70, 74).
Among the drug combinations tested, neomycin plus polymyxin
B (33, 42, 45, 46, 52) and neomycin sulfate plus polymyxin B
sulfate plus gramicidin (cation detergent) exhibited amoebicidal
properties (42, 45, 53). In contrast, the combination of neomycin
plus polymyxin B plus bacitracin exhibited amoebistatic and
amoebicidal as well as cysticidal properties (18, 40, 51, 65, 76).
Several other protein synthesis inhibitors tested show amoebi-
cidal properties but have limited cysticidal effects. These include
prednisolone (irreversibly binds with glucocorticoid receptors,
inhibiting gene transcription for cytochrome oxidase 2 [COX-2],
cytokines, cell adhesion molecules, and inducible NO synthase)
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(52), beta-methasone phosphate (binds to plasma transcortin and
becomes active when it is not bound to transcortin) (81), and
linezolid (inhibits the formation of subunits of ribosome) (39, 41,
50, 51, 71, 72).
ENZYME-ACTING AGENTS
As described above, quaternary ammonium compounds (such as
cetyltrimethylammonium bromide and cetylpyridinium bro-
mide) and alkylphosphocholines (such as miltefosine) are prom-
ising candidates against Acanthamoeba infections. The mode of
action of miltefosine is induction of apoptosis-like cell death by
acting as an inhibitor of proteinase kinase B. It has been shown to
exhibit amoebicidal properties (61, 82–84). Notably, miltefosine
(at 65.12 g per ml) was tested in combination with polyhexam-
ethylene biguanide, chlorhexidine, and propamidine isethionate
in a rat model for the topical treatment of Acanthamoeba keratitis
(83). The results revealed that themiltefosine-polyhexamethylene
biguanide combination gave the best treatment results, and ap-
proximately 86% of the eyes were cleared of amoebae. It is also
recommended as part of the treatment regimen against human
brain infection due to Acanthamoeba (85). Future studies of the
combination and effective delivery of quaternary ammonium
compounds and their derivatives to the target site will determine
the clinical usefulness. Other drugs tested showed amoebicidal
effects but limited cysticidal effects. These include sulfadiazine
(inhibitor of dihydropteroate synthetase) (86, 87), flurbiprofen
(nonselective cytochrome oxidase [COX] inhibitor of pathway
responsible for the conversion of arachidonic acid into prosta-
glandin G2 into prostaglandin H2) (77), riboflavin (targeting ri-
boflavin hydrogenase, riboflavin kinase, and riboflavin synthase)
(88), diclofenac (inhibitor of prostaglandin synthesis by inhibit-
ing COX) (13), albendazole (targeting the colchicine-sensitive site
of tubulin, inhibiting its polymerization into microtubules and
leading to impaired uptake of glucose and depletion of glycogen
stores) (89), and digoxin, which binds to the sodium/potassium-
transporting ATPase alpha-1 chain (68).
Given the rarity of the disease and availability of a number of
compounds with various effects against Acanthamoeba trophozo-
ites and cysts, there is a need to test various combinations to prove
their clinical usefulness with tolerable toxicities and acceptable
pharmacokinetics profiles, safety margins, etc. In the absence of
targeted therapy, this would provide the logical avenues for fur-
ther research in clinical practice that may provide strategies for
chemotherapy against this difficult-to-treat infection.
THE WAY FORWARD
The search for safe and effective antiacanthamoebic drugs remains
a challenge. Research over the past few decades has identified a
large number of compounds that have therapeutic potential, but
their translational value has not been explored. As discussed
above, independent laboratories have done the groundwork in
identifying several molecular targets and have identified several
drugs of potential therapeutic value and used lead compounds for
synthesis of derivatives; however, that work did not gain the at-
tention of the major pharmaceutical companies, whose participa-
tion is needed to carry out the expensive in vivo studies as well as
the clinical trials. Although the lack of interest of the pharmaceu-
tical industry in finding cures for parasitic infections is well
known, it is worth noting that eye infection due to the Acantham-
oeba parasite occurs in contact lens wearers. The number of con-
tact lens wearers was estimated at 125million in 2004, worldwide,
with approximately 35 million contact lens wearers in the United
States alone (90). The contact lens market was estimated at $6.1
billion in 2010, and it was estimated that the global market would
reach $11.7 billion by 2015 (91). For a multi-billion-dollar indus-
try, it is puzzling that pharmaceutical companies are not investing
in this research, especially as novel molecules/inhibitors/drugs
and their clinical applications can be patented, which offers tre-
mendous commercial value. Notably, several companies have
agreed to pay billions of dollars to settle lawsuits and have also
withdrawn contact lenses/disinfectants from the market for being
ineffective against Acanthamoeba or Fusarium. This makes no fi-
nancial sense. It is far more economical to develop effective con-
tact lens disinfectants against Acanthamoeba. Although the ability
of amoebae to switch phenotypes into a dormant cyst form is a
major hindrance in the development of effective contact lens dis-
infectants and/or chemotherapeutic approaches, recent studies
have shown that the addition of cellulase enzyme to disrupt cyst
wall structure renders amoeba cysts susceptible to the effects of
antiamoebic drugs (92). The combination of antiamoebic agent
and cellulase enzyme was shown to abolish the viability of both
cysts and trophozoites. Notably, none of the agents, when tested
alone, completely destroyed cysts and trophozoites, suggesting
that the use of cellulose-degradingmolecules is a useful avenue for
targeted killing of amoebae. As cellulose synthesis is absent in
mammalian cells, the use of cellulose-degradingmolecules in con-
tact lens disinfectants as well as in drug formulations in the treat-
ment of Acanthamoeba infection needs to be explored.
It is hoped that the recent completion of the Acanthamoeba
genome (93) will expedite identification of novel drug targets fur-
ther, through genomics, proteomics, and bioinformatics. Among
the existing drugs/disinfectants, given that they are limited in ef-
ficacy, there is a need to find ways to enhance their efficacy. The
constituents of contact lens disinfectants must be carefully se-
lected to target the cyst stage of amoebae. For example, the recall of
Complete MoisturePlus contact lens disinfectant (AMO, Santa
Ana, CA) following an outbreak of Acanthamoeba keratitis re-
vealed that one of the constituents of the solution, propylene gly-
col, induced encystation inAcanthamoeba, resulting in the forma-
tion of cysts, which are resistant to the majority of contact lens
disinfectants. Similarly, treatment is problematic due to specificity
andparasite dormancy. The use of a carrier for antiacanthamoebic
drug delivery is an important avenue that could yield promising
results without affecting host cell viability. For eye infections,
mannose- or antibody- or Fab-conjugated drugs should allow
specific targeting of drugs toAcanthamoeba. Notably, recent stud-
ies showed that conjugation of mannose with photodynamic
compounds allows specific targeting of Acanthamoeba and en-
hances their antiacanthamoebic effects (66). These findings sug-
gested that specific antibodies or antiacanthamoebic agents, cou-
pled with selective cytotoxic agents, could be useful in the
treatment of Acanthamoeba infections, as they can be minimally
invasive and minimally toxic to the host cells. Alternatively, par-
asite-specific pathways, such as ergosterol biosynthesis or cellu-
lose biosynthesis, and the underlying enzymes that are required
for the makeup of these molecules offer important targets for the
rational development of therapeutic interventions.
Additionally, liposome-complexed antiamoebic drugs have
shown promising in vitro results in enhanced killing of pathogenic
Acanthamoeba compared with the use of the drugs alone (94).
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Moreover, liposomal ergosterol-pentamidine proved effective in
preventing parasite-mediated host cell cytotoxicity in vitro (94),
suggesting that ergosterol-formulated liposomes hold promise in
the targeted delivery of drugs. The pace of research in identifying
and characterizing novel targets has yielded promising results;
however, the translational value for therapeutic interventions re-
quires further investigation. The recent research shift to pheno-
typic screening against the whole parasite, as well as to repurpos-
ing of drugs, i.e., screening of FDA-approved drugs to identify
those with antiacanthamoebic activity (68), is auspicious and has
the potential to open several avenues for further research. Once
active compounds are identified, the approval process can be ex-
pedited, as the drugs are already being used for clinical applica-
tions against other diseases. Moreover, several animal-based,
plant-based, and microbe-based molecules have been identified
that show antiacanthamoebic effects. Some of the aforementioned
components represent appealing therapeutic targets that need to
be exploited in future studies. With the availability of relevant
disease models and of assays for target validation, there is an ur-
gent need to develop translational research by encouraging aca-
demia-industry partnerships, which offer tremendous opportuni-
ties of commercial and scientific value.
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